WO2023218305 - METHOD FOR INACTIVATION OF SARS-COV-2
National phase entry is expected:
Publication Number
WO/2023/218305
Publication Date
16.11.2023
International Application No.
PCT/IB2023/054697
International Filing Date
05.05.2023
Title **
[English]
METHOD FOR INACTIVATION OF SARS-COV-2
[French]
PROCÉDÉ D'INACTIVATION DU SARS-COV-2
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
ROTH, Bernhard
STOKES, Anne
WILSON, Eileen
Priority Data
63/339,761
09.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1967 | |
| EPO | Filing, Examination, Granting | 8113 | |
| Japan | Filing, Examination, Granting | 2091 | |
| South Korea | Filing, Examination, Granting | 1945 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,456
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides a method for inactivating SARS-CoV-2 in a sample comprising at least one recombinant protein, wherein the method comprises treating the sample at a pH of between 2.6 and 3.4.[French]
L'invention présente un procédé d'inactivation du SARS-CoV-2 dans un échantillon comprenant au moins une protéine recombinée, le procédé comprenant le traitement de l'échantillon à un pH compris entre 2,6 et 3,4.